A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy

• DOI: 10.3389/fimmu.2025.1539076
• Publication Date: 2025-05-02T11:42:59Z
• Authors: Yinmei Xu; Xin Wu; Peng Zhi; Genyu Guo; Yankan Fu; Lukuan You; Siyuan Huai; Jianxiong Li
• Keywords: Microsatellite Instability

Background LRFN4, characterized by leucine-rich repeats and fibronectin type III domains, has been implicated in various human diseases. However, its role immune regulation cancer prognosis remains unclear. Methods We performed a comprehensive analysis using datasets from The Cancer Genome Atlas (TCGA), Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression Project (GTE x), UALCAN, Star Base, Comparative Toxicogenomics Database (CTD), observed significant dysregulation of LRFN4 multiple cancers compared to normal tissues. Results expression was strongly correlated with clinical prognosis, subtypes, molecular checkpoint (ICP) genes, tumor mutational burden (TMB), microsatellite instability (MSI), infiltration, which were measured ESTIMATE scores. Moreover, associated the presence tumor-infiltrating cells, particularly gastrointestinal tumors, reflecting cell genetic signatures. Validation through fluorescence multiplex immunohistochemistry confirmed that association protein clinicopathological features microenvironment gastric cancer. Flow cytometry indicated inhibited apoptosis lines while enhancing cycle arrest S phase. Western Blot demonstrated positive correlation between high levels cyclin D1 as well CDK4. In contrast, negative level cleaved-caspase-3 levels. Conclusion These findings suggest may serve novel biomarker for potential target immunotherapy.